Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma

Keren Rouvinov; Lidia Osyntsov; Ruthy Shaco-Levy; Nina Baram; Samuel Ariad; Wilmosh Mermershtain

doi:10.1016/j.clgc.2017.05.028

Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma

Clin Genitourin Cancer. 2017 Dec;15(6):e1127-e1130. doi: 10.1016/j.clgc.2017.05.028. Epub 2017 Jun 3.

Authors

Keren Rouvinov¹, Lidia Osyntsov², Ruthy Shaco-Levy², Nina Baram³, Samuel Ariad⁴, Wilmosh Mermershtain⁴

Affiliations

¹ Department of Oncology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. Electronic address: kerenro@clalit.org.il.
² Department of Pathology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
³ Department of Radiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
⁴ Department of Oncology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

PMID: 28673798
DOI: 10.1016/j.clgc.2017.05.028

No abstract available

Keywords: Chromophobe renal cell carcinoma; Nivolumab; Non–clear-cell renal cell carcinoma; Programmed death 1 inhibitor; Sarcomatoid transformation.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / secondary
Cell Transformation, Neoplastic / drug effects*
Cell Transformation, Neoplastic / pathology
Humans
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / pathology
Male
Middle Aged
Nivolumab
Prognosis
Sarcoma / drug therapy*
Sarcoma / secondary

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab